{"preliminary_commentary":{"by_channel":{"youtube":21,"podcast":9,"x_thread":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04529772\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ESCALADE","nct_id":"NCT04529772","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=escalade-nct04529772. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ESCALADE","arms":[{"description":"Acalabrutinib plus Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)","label":"acalabrutinib + R-CHOP","type":"EXPERIMENTAL"},{"description":"Placebo plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)","label":"placebo + R-CHOP","type":"PLACEBO_COMPARATOR"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2027-02-22","type":"ESTIMATED"},"conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":{"count":611,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"acalabrutinib","otherNames":[],"type":"DRUG"},{"name":"placebo","otherNames":[],"type":"DRUG"},{"name":"Prednisone","otherNames":[],"type":"DRUG"},{"name":"Rituximab","otherNames":[],"type":"DRUG"},{"name":"Cyclophosphamide","otherNames":[],"type":"DRUG"},{"name":"Vincristine","otherNames":[],"type":"DRUG"},{"name":"Doxorubicin","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-13","lead_sponsor":"Acerta Pharma BV","official_title":"Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤75 Years With Previously Untreated Non-GCB DLBCL","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-02-22","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) per the Lugano Classification for NHL in Arm A compared to Arm B","timeFrame":"at every single visit up to 60 months"}],"references":[],"start_date":{"date":"2020-10-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","url":"https://clinicaltrials.gov/study/NCT04529772"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/escalade-nct04529772"}